Roche is investing in an early-stage project that takes a novel approach to treating autoimmune diseases, agreeing to pay up to $580 million for California's Adheron Therapeutics.
Sorrento Therapeutics, among the constellation of companies associated with billionaire Patrick Soon-Shiong, is again widening its R&D mission with a joint venture, teaming up with a California cancer center on some novel antibody technology.
Under-the-radar biotech startup Alector raised $32 million in Series C funds to support its early-stage work in neurodegenerative disease, recruiting some high-profile investors as it develops a novel approach to brain-destroying disorders.
Amgen is teaming up with Xencor through a heavily back-loaded deal worth as much as $1.7 billion, collaborating on 6 early-stage programs in immuno-oncology and inflammation.
Back at the beginning of 2014, a fast-growing Regeneron revealed that it had been building a new genetics research center that would zero in on carefully targeted diseases as it built new drug development programs from the ground up. Eighteen months later the big biotech says the effort--led by some top researchers wooed in to run the operation--has paid off with a clear target for a rare genetic bone disease. And they have an antibody in preclinical testing that could correct the disorder.
Amgen's investigational bone-growing drug met its main goal in a late-stage trial, clearing its first Phase III hurdle by besting an Eli Lilly blockbuster for osteoporosis.
A new drug for blood cancer from Bristol-Myers Squibb and AbbVie is on the fast track to FDA approval, winning a priority review to treat multiple myeloma.
MorphoSys has moved to add targets for its immuno-oncology arsenal. The agreement sees MorphoSys gain access to tumor-associated peptides discovered by its compatriot Immatics Biotechnologies in exchange for some of its antibodies, with both companies paying out milestones as their respective programs advance.
Novo Nordisk is jumping on Genmab's antibody development platform in search of two new drug programs--and this time the Danish biotech company will not be focused on another cancer pact.
Roche is resuscitating development for gantenerumab, an Alzheimer's treatment that flamed out in Phase III late last year, as recent clinical results have emboldened the company to launch new studies.